Use of enteral access for continuous delivery of levodopa-carbidopa in patients with advanced Parkinson's disease - 23/03/16
Résumé |
Introduction and aim |
Continuous delivery to the jejunum of levodopa-carbidopa is a promising therapy in patients with advanced Parkinson's disease, as it reduces motor fluctuation. Percutaneous endoscopic gastrostomy and jejunal tube placement is a suitable option for this. However, studies focused in percutaneous endoscopic gastrostomy and jejunal tube management are lacking. We report our experience regarding this technique, including technical success, adverse events and outcomes, in patients with advanced Parkinson's disease.
Material and methods |
Twenty-seven advanced patients with Parkinson's disease (17 men, median age: 64years, median disease duration: 11years) were included in a retrospective study from June 2007 to April 2015. The median follow- up period was 48months [1–96months].
Results |
No adverse event was noted during and after nasojejunal tube insertion (to assess treatment efficacy). After a good therapeutic response, a percutaneous endoscopic gastrostomy and jejunal tube was placed successfully in all patients. The percutaneous endoscopic gastrostomy tube was inserted according to the Ponsky's method. The jejunal extension was inserted during the same procedure in all patients. Twelve patients (44%) experienced severe adverse events related to the percutaneous endoscopic gastrostomy and jejunal tube insertion, which occurred after a median follow-up of 15.5months. Endoscopy was the main treatment modality. Patients who experienced severe adverse events had higher comorbidity score (P=0.011) but were not older (P=0.941) than patients who did not.
Conclusions |
While all patients responded well to levodopa-carbidopa regarding neurological outcomes, severe adverse events were frequent and related with comorbidities. Endoscopic treatment is the cornerstone for management of percutaneous endoscopic gastrostomy and jejunal tube-related events. In conclusion, clinicians, endoscopists, as well as patients, should be fully informed of procedure-related adverse events and patients should be followed in centres experienced in their management.
Le texte complet de cet article est disponible en PDF.Plan
Vol 30 - N° 1
P. 65 - mars 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?